Protocols: Tillman Gerngross's Avitide goes back to the well for more venture cash; Novartis leads $17M startup round
A year ago, Avitide CEO Kevin Isett told me that a $7.6 million round would be plenty to take the protein therapeutic company to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
